GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses

Схожие документы

• Biologic Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated with GM-CSF (Sargramostim) as Adjuvant Therapy of Melanoma
  по: Spitler, Lynn E., et al.
  Опубликовано: (2017)
• Single Institution Experience of Ipilimumab 3 mg/kg with Sargramostim (GM-CSF) in Metastatic Melanoma
  по: Luke, Jason J., et al.
  Опубликовано: (2015)
• Adjuvant GM-CSF Improves Survival in High Risk Stage IIIc Melanoma: A Single Center Study
  по: Grotz, Travis E., et al.
  Опубликовано: (2014)
• Pre-existing levels of CD4 T cells expressing PD-1 are related to overall survival in prostate cancer patients treated with ipilimumab
  по: Kwek, Serena S., et al.
  Опубликовано: (2015)
• Safety and immunologic correlates of Melanoma GVAX, a GM-CSF secreting allogeneic melanoma cell vaccine administered in the adjuvant setting
  по: Lipson, Evan J, et al.
  Опубликовано: (2015)